Abstract
Neonatal enteroviral sepsis is a potentially fatal condition. Perinatally acquired infection and severe coagulopathy can be associated with a poor clinical outcome, and antiviral therapy is currently unavailable. Pocapavir (V-073) is an investigational drug candidate being developed for poliovirus indications, but also has variable antiviral activity against nonpolio enteroviruses. We describe the first use of pocapavir in treating a case of severe neonatal enteroviral sepsis due to Coxsackievirus B3.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 52-54 |
| Number of pages | 3 |
| Journal | Pediatric Infectious Disease Journal |
| Volume | 34 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2015 |
Keywords
- Coxsackievirus
- Neonatal enterovirus infection
- Pocapavir
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Microbiology (medical)
- Infectious Diseases
Fingerprint Dive into the research topics of 'First use of investigational antiviral drug pocapavir (V-073) for treating neonatal enteroviral sepsis'. Together they form a unique fingerprint.
Cite this
Torres-Torres, S., Myers, A. L., Klatte, J. M., Rhoden, E. E., Oberste, M. S., Collett, M. S., & McCulloh, R. J. (2015). First use of investigational antiviral drug pocapavir (V-073) for treating neonatal enteroviral sepsis. Pediatric Infectious Disease Journal, 34(1), 52-54. https://doi.org/10.1097/INF.0000000000000497